These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 7897383)

  • 1. Cost-effectiveness analysis of vaccination against hepatitis A in travellers.
    Van Doorslaer E; Tormans G; Van Damme P
    J Med Virol; 1994 Dec; 44(4):463-9. PubMed ID: 7897383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of hepatitis A prevention in travellers.
    Tormans G; Van Damme P; Van Doorslaer E
    Vaccine; 1992; 10 Suppl 1():S88-92. PubMed ID: 1335668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of hepatitis A antibodies among Israeli travellers and the economic feasibility of screening before vaccination.
    Schwartz E; Raveh D
    Int J Epidemiol; 1998 Feb; 27(1):118-20. PubMed ID: 9563704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effective analysis of hepatitis A prevention in Ireland.
    Rajan E; Shattock AG; Fielding JF
    Am J Gastroenterol; 2000 Jan; 95(1):223-6. PubMed ID: 10638588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic evaluation of vaccination against hepatitis A for frequent travellers.
    Fenn P; McGuire A; Gray A
    J Infect; 1998 Jan; 36(1):17-22. PubMed ID: 9515663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in hepatitis A prevention in travellers.
    Steffen R; Gyurech D
    J Med Virol; 1994 Dec; 44(4):460-2. PubMed ID: 7897382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Screening policy for travellers from Rotterdam for hepatitis A antibodies prior to eventual immunization: favourable cost-benefit ratio].
    Reintjes R; Bosman A; de Zwart O
    Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1777-80. PubMed ID: 10494329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of hepatitis A virus immunisation in Spain.
    Arnal JM; Frisas O; Garuz R; Antoñanzas F
    Pharmacoeconomics; 1997 Sep; 12(3):361-73. PubMed ID: 10170461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing hepatitis A infections in travelers to endemic areas.
    Koff RS
    Am J Trop Med Hyg; 1995 Dec; 53(6):586-90. PubMed ID: 8561258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.
    Bryan JP; Nelson M
    Arch Intern Med; 1994 Mar; 154(6):663-8. PubMed ID: 8129500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis A antibodies in attenders of London Travel Clinics: cost-benefit of screening prior to hepatitis A immunisation.
    Zuckerman JN; Powell L
    J Med Virol; 1994 Dec; 44(4):393-4. PubMed ID: 7897370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of hepatitis A prevention in France.
    Severo CA; Fagnani F; Lafuma A
    Pharmacoeconomics; 1995 Jul; 8(1):46-61. PubMed ID: 10155601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis A antibody titres after infection and immunization: implications for passive and active immunization.
    Zaaijer HL; Leentvaar-Kuijpers A; Rotman H; Lelie PN
    J Med Virol; 1993 May; 40(1):22-7. PubMed ID: 8515245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The efficacy of the prevaccination detection of anti-HAV in hepatitis A vaccination programs].
    Navas E; Bayas JM; Bruguera M; Vidal J; Galí N; Taberner JL; Salleras L
    Med Clin (Barc); 1995 Jul; 105(5):168-71. PubMed ID: 7630228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost analysis of two strategies for preventing hepatitis A virus infection in Spanish travellers to developing countries.
    Bayas JM; González A; Vilella A; San-Martín M; Bertran MJ; Adell C
    Epidemiol Infect; 2001 Oct; 127(2):347-51. PubMed ID: 11693513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of a publicly funded hepatitis A travel vaccination program in Ontario, Canada.
    Ramsay LC; Anyiwe K; Li M; Macdonald L; Coyte PC; Sander B
    Vaccine; 2019 Mar; 37(11):1467-1475. PubMed ID: 30770225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The value of screening serology in anti-hepatitis A vaccination of travelers].
    Landry P; Darioli R
    Schweiz Med Wochenschr; 1998 Apr; 128(15):581-5. PubMed ID: 9606799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic treatment regimens for the prevention of hepatitis A. Current concepts.
    Kendall BJ; Cooksley WG
    Drugs; 1991 Jun; 41(6):883-8. PubMed ID: 1715265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for Prevention of Hepatitis A Based on a Cost-Effectiveness Analysis.
    Tormans G; Van Damme P ; Van Doorslaer E
    J Travel Med; 1994 Sep; 1(3):127-135. PubMed ID: 9815326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis A infection: a seroepidemiological study in young adults in North-East Italy.
    Moschen ME; Floreani A; Zamparo E; Baldo V; Majori S; Gasparini V; Trivello R
    Eur J Epidemiol; 1997 Dec; 13(8):875-8. PubMed ID: 9476815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.